inclisiran
Selected indexed studies
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (N Engl J Med, 2020) [PMID:32187462]
- Inclisiran: First Approval. (Drugs, 2021) [PMID:33620677]
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. (Cardiovasc Res, 2024) [PMID:38753448]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. (2020) pubmed
- Inclisiran: First Approval. (2021) pubmed
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. (2024) pubmed
- Inclisiran: A Review in Hypercholesterolemia. (2023) pubmed
- Inclisiran. (2012) pubmed
- Inclisiran: a new generation of lipid-lowering siRNA therapeutic. (2023) pubmed
- Inclisiran. (2006) pubmed
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. (2020) pubmed
- Inclisiran for the treatment of hypercholesterolaemia. (2024) pubmed
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. (2023) pubmed